Cargando…
Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B
BACKGROUND: Microvascular invasion (MVI) is recognized as a prognostic factor associated with poor outcome in hepatocellular carcinoma (HCC) patients after curative resection. It remains unclear, however, whether MVI can provide prognostic information for patients at a specific tumor stage. METHODS:...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240309/ https://www.ncbi.nlm.nih.gov/pubmed/28095820 http://dx.doi.org/10.1186/s12885-017-3050-x |
_version_ | 1782496043390205952 |
---|---|
author | Huang, Cheng Zhu, Xiao-Dong Ji, Yuan Ding, Guang-Yu Shi, Guo-Ming Shen, Ying-Hao Zhou, Jian Fan, Jia Sun, Hui-Chuan |
author_facet | Huang, Cheng Zhu, Xiao-Dong Ji, Yuan Ding, Guang-Yu Shi, Guo-Ming Shen, Ying-Hao Zhou, Jian Fan, Jia Sun, Hui-Chuan |
author_sort | Huang, Cheng |
collection | PubMed |
description | BACKGROUND: Microvascular invasion (MVI) is recognized as a prognostic factor associated with poor outcome in hepatocellular carcinoma (HCC) patients after curative resection. It remains unclear, however, whether MVI can provide prognostic information for patients at a specific tumor stage. METHODS: Consecutive HCC patients who underwent curative resection in years of 2007 and 2008 (discovery cohort) were enrolled in this retrospective study. Patients were stratified by the Barcelona Clinic Liver Cancer (BCLC) staging system. The prognostic significance of MVI for overall survival (OS) and recurrence-free survival (RFS) was studied in each subgroup. The clinical significance of MVI was validated in another cohort of patients underwent curative surgery in the year of 2006 (validation cohort). RESULTS: Of the 1540 patients in the discovery cohort, 389 (25.3%) patients had detectable MVI. Occurrence rates of MVI in the BCLC stage 0, A, and B subgroups were 12.4, 26.2, and 34.4%, respectively. In univariate analysis, MVI was associated with poor OS and RFS (P < 0.001 for both) in HCC patients at stage A, with poor OS in patients at stage 0 (P = 0.028), and with poor RFS at stage B (P = 0.039). In multivariate analysis, MVI was an independent risk factor for OS (HR = 1.431, 95% CI, 1.163–1.761, P < 0.001) and RFS (HR = 1.400, 95% CI, 1.150–1.705, P = 0.001) in patients at stage A; and an independent risk factor for RFS (P = 0.043) in patients at stage B. A similar clinical significance of MVI was found in the validation cohort. CONCLUSIONS: MVI has limited prognostic value for HCC patients at BCLC stages 0 and B. For those at stage A, MVI was associated with patient survival and may help to select patients with high risk of disease recurrence. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3050-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5240309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52403092017-01-19 Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B Huang, Cheng Zhu, Xiao-Dong Ji, Yuan Ding, Guang-Yu Shi, Guo-Ming Shen, Ying-Hao Zhou, Jian Fan, Jia Sun, Hui-Chuan BMC Cancer Research Article BACKGROUND: Microvascular invasion (MVI) is recognized as a prognostic factor associated with poor outcome in hepatocellular carcinoma (HCC) patients after curative resection. It remains unclear, however, whether MVI can provide prognostic information for patients at a specific tumor stage. METHODS: Consecutive HCC patients who underwent curative resection in years of 2007 and 2008 (discovery cohort) were enrolled in this retrospective study. Patients were stratified by the Barcelona Clinic Liver Cancer (BCLC) staging system. The prognostic significance of MVI for overall survival (OS) and recurrence-free survival (RFS) was studied in each subgroup. The clinical significance of MVI was validated in another cohort of patients underwent curative surgery in the year of 2006 (validation cohort). RESULTS: Of the 1540 patients in the discovery cohort, 389 (25.3%) patients had detectable MVI. Occurrence rates of MVI in the BCLC stage 0, A, and B subgroups were 12.4, 26.2, and 34.4%, respectively. In univariate analysis, MVI was associated with poor OS and RFS (P < 0.001 for both) in HCC patients at stage A, with poor OS in patients at stage 0 (P = 0.028), and with poor RFS at stage B (P = 0.039). In multivariate analysis, MVI was an independent risk factor for OS (HR = 1.431, 95% CI, 1.163–1.761, P < 0.001) and RFS (HR = 1.400, 95% CI, 1.150–1.705, P = 0.001) in patients at stage A; and an independent risk factor for RFS (P = 0.043) in patients at stage B. A similar clinical significance of MVI was found in the validation cohort. CONCLUSIONS: MVI has limited prognostic value for HCC patients at BCLC stages 0 and B. For those at stage A, MVI was associated with patient survival and may help to select patients with high risk of disease recurrence. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3050-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-17 /pmc/articles/PMC5240309/ /pubmed/28095820 http://dx.doi.org/10.1186/s12885-017-3050-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Huang, Cheng Zhu, Xiao-Dong Ji, Yuan Ding, Guang-Yu Shi, Guo-Ming Shen, Ying-Hao Zhou, Jian Fan, Jia Sun, Hui-Chuan Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B |
title | Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B |
title_full | Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B |
title_fullStr | Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B |
title_full_unstemmed | Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B |
title_short | Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B |
title_sort | microvascular invasion has limited clinical values in hepatocellular carcinoma patients at barcelona clinic liver cancer (bclc) stages 0 or b |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240309/ https://www.ncbi.nlm.nih.gov/pubmed/28095820 http://dx.doi.org/10.1186/s12885-017-3050-x |
work_keys_str_mv | AT huangcheng microvascularinvasionhaslimitedclinicalvaluesinhepatocellularcarcinomapatientsatbarcelonacliniclivercancerbclcstages0orb AT zhuxiaodong microvascularinvasionhaslimitedclinicalvaluesinhepatocellularcarcinomapatientsatbarcelonacliniclivercancerbclcstages0orb AT jiyuan microvascularinvasionhaslimitedclinicalvaluesinhepatocellularcarcinomapatientsatbarcelonacliniclivercancerbclcstages0orb AT dingguangyu microvascularinvasionhaslimitedclinicalvaluesinhepatocellularcarcinomapatientsatbarcelonacliniclivercancerbclcstages0orb AT shiguoming microvascularinvasionhaslimitedclinicalvaluesinhepatocellularcarcinomapatientsatbarcelonacliniclivercancerbclcstages0orb AT shenyinghao microvascularinvasionhaslimitedclinicalvaluesinhepatocellularcarcinomapatientsatbarcelonacliniclivercancerbclcstages0orb AT zhoujian microvascularinvasionhaslimitedclinicalvaluesinhepatocellularcarcinomapatientsatbarcelonacliniclivercancerbclcstages0orb AT fanjia microvascularinvasionhaslimitedclinicalvaluesinhepatocellularcarcinomapatientsatbarcelonacliniclivercancerbclcstages0orb AT sunhuichuan microvascularinvasionhaslimitedclinicalvaluesinhepatocellularcarcinomapatientsatbarcelonacliniclivercancerbclcstages0orb |